Targeted therapy for pancreatic cancer with high risk of return
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests if personalized medicines, chosen based on the genetic profile of your tumor, can help prevent pancreatic cancer from coming back after surgery. It is for people who have had their pancreatic tumor removed but have features that suggest a higher chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had surgery to remove a pancreatic tumor (not a neuroendocrine tumor).
- After surgery, you either received chemotherapy or radiation, or you were not able or chose not to have those treatments.
- You have either a high CA 19-9 blood level (above 35) at least 6 weeks after surgery, or your pathology report shows a positive margin or cancer in lymph nodes.
- You do not have any signs of cancer spread or return on your most recent scans.
- You are willing to have your case reviewed by a special tumor board and to take the medicine they recommend.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how doctors choose individualized cancer treatment for people with pancreatic cancer. It may help them learn which treatment choices work best for different patients.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
This trial tests a combination of drugs (nimotuzumab, nab-paclitaxel, and gemcitabine) given before and after surgery for pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach improves outcomes.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests treatments that are chosen specifically for you based on the genetic makeup of your tumor. The goal is to find a targeted therapy that may work better for your advanced pancreatic cancer after standard chemotherapy has stopped being effective.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.